Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EURIPIDES

Financiado

Cerrado

EUropean Research initiative to develop Imaging Probes for early In vivo Diagnos...

EUropean Research initiative to develop Imaging Probes for early In vivo Diagnosis and Evaluation of response to therapeutic Substances "We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeuti... ver más

31/07/2012

UNIVERSITY COLLEGE...

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-07-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

UNIVERSITY COLLEGE LONDON

1.11M€ | Lider

SEIN

166.68K€ | Participante

GABO:mi

495.91K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BtRAIN Brain barriers training 3M€ Cerrado

CONNECT Connecting neural networks Nervous system on Chip Technolog... 7M€ Cerrado

NovelTAP Novel diagnostic Tools for Alzheimer s and Parkinson s disea... 160K€ Cerrado

NOMAD Network Neurodegeneration in Alzheimer s Disease 270K€ Cerrado

Oligomers Characterising protein oligomers and their role in neurodege... 2M€ Cerrado

NVU-Chip An in vitro 3D microfluidic human NeuroVascular Unit model f... 157K€ Cerrado

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 9M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). Overactivity of these efflux transporters results in inadequate access of CNS drugs to their targets and hampers the build up of adequate tissue levels of these drugs in the brain, greatly limiting their therapeutic efficacy. As such, this ""transporter hypothesis"" of drug resistance is applicable to a broad range of CNS drugs and patients with a variety of CNS diseases who critically depend on these drugs. Efflux transporters may also influence brain elimination of Aβ, the hallmark of Alzheimer’s disease (AD). Impaired multidrug transporter function with reduced clearance of Aβ could lead to accumulation within the extracellular space, contributing to the pathogenesis of AD. We will determine the contribution of multidrug transporters to impaired brain uptake of drugs for the prediction of therapeutic responses, or the contribution of impaired transporter function to reduced clearance of toxic substances for the early in-vivo diagnosis of AD. Circumvention of pharmacoresistance, or increasing clearance, may involve inhibitors of multidrug transporters or sophisticated alternative therapies, but demonstration of overexpression or underactivity of transporter function is an essential and necessary first step. An in-vivo imaging biomarker of multidrug transporter function is essential for identifying altered transporter activity in individual patients. If a relation between overexpression and therapy resistance, or underactivity and AD, can be demonstrated, such a biomarker will provide the means for predicting treatment response, or early diagnosis, in individual patients."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores